Skip to main content

Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings

Lead Author: Sandy Morris, BA, BS, MBA & Philip Green, BS (Presenter)

Published: International Symposium on ALS-MND (MNDA)

Date: December 5 - 9, 2022

Read more (opens new window)

Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)

Lead Author: Shide Badri, MD, MPH

Published: International Symposium on ALS-MND (MNDA)

Date: December 5 - 9, 2022

Read more (opens new window)

Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)

Lead Author: Leonard H. van den Berg, MD, PhD

Published: International Symposium on ALS-MND (MNDA)

Date: December 5 - 9, 2022

Read more (opens new window)

Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2

Lead Author: Mathias Leinders, PhD

Published: Society for Neuroscience (SfN)

Date: November 12 - 16, 2022

Read more (opens new window)

Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis

Lead Author: Nicole Shuckett, RD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: November 2, 2022

Read more (opens new window)

Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration

Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: November 1, 2022

Read more (opens new window)

Reduced Plasma Concentration of the Neuroinflammation Biomarker Chitinase-3-Like Protein (CHI3L1/YKL-40) in the CENTAUR Trial

Lead Author: Robert Bowser, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: November 1, 2022

Read more (opens new window)

International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)

Lead Author: Leonard H. van den Berg, MD, PhD

Published: International Congress on Neuromuscular Diseases (ICNMD)

Date: July 9, 2022

Read more (opens new window)

Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results

Lead Author: Tracey Jason, PhD, Head of Medical Affairs at Amylyx Pharmaceuticals Canada

Published: Canadian Neurological Sciences Federation (CNSF)

Date: June 26, 2022

Read more (opens new window)

Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results

Lead Author: Lahar Mehta, MD, Head of Global Clinical Development at Amylyx Pharmaceuticals

Published: European Network to Cure ALS (ENCALS)

Date: June 2, 2022

Read more (opens new window)